Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Arginine + carvedilol** is a combination product containing two active substances: L-arginine, a conditionally essential amino acid involved in nitric oxide (NO) synthesis, and carvedilol, a non-selective beta-adrenergic and alpha-1 adrenergic receptor antagonist (beta-blocker). This combination has been explored for potential synergistic effects in cardiovascular disease, particularly for *hypertension*, *left ventricular dysfunction*, and *heart failure*, as well as for reducing peptic ulcer severity and oxidative stress in experimental models. Arginine increases endogenous NO (vasodilator, gastroprotectant) and carvedilol reduces blood pressure and heart rate by blocking adrenergic receptors. The exact clinical efficacy and approval status of this specific combination is limited; one formulation under the brand HYPERTENEVIDE-12.5 was marketed by Physician Therapeutics in the US as an unapproved kit.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on arginine + carvedilol.